Altamira expects its operating expenses to decrease significantly in 2026, following the planned spin-off of its ATAG subsidiary and termination of US SEC reporting duties, with updated guidance to follow.
Bullish
Altamira significantly reduced its net loss and operating loss, expanded its nucleic acid delivery platform with new applications, and saw its associate achieve key regulatory approvals and a milestone payment.
Bearish
Altamira experienced a significant decrease in shareholders' equity and a substantial increase in current liabilities, including new loans, while relying on external partnerships for CNS pipeline advancement.